Objective: To study the effects of epalrestat combined with taurine on the efficacy of cataract in diabetic patients and its effects on inflammation and oxidative stress factors. Methods: 90 cases(152 eyes) of diabetic cataracts were randomly divided into the observation group and the control group. The observation group consisted of 45 cases (75 eyes) and the control group consisted of 45 cases (77 eyes). Both groups were treated with phacoemulsification and intraocular lens implantation. The control group was given taurine eye drops, and the observation group was given epalrestat on the basis of the control group. Before and after treatment, daily visual acuity examination was performed using standard logarithmic visual acuity chart. The anterior segment complication was scored before and 3, 7, 14 days after surgery. Serum malondialdehyde (MDA), superoxide dismutase (SOD) and total antioxidant capacity (TAC) levels was measured before and after treatment. Quality of life (QOL) assessment was performed using the QOL questionnaire from the National Ophthalmology Institute. Results: The proportion of corrected visual acuity of 0.5 in the observation group was significantly higher than that in the control group (P<0.05). The results of variance analysis of repeated measurements showed that the synthetical evaluation of anterior segment symptoms in the control group and the observation group decreased in 3, 7 and 14 days after operation, while the synthetical evaluation of anterior segment symptoms in the observation group was lower than that in the control group, the difference was significant (P<0.001). The difference of MDA, SOD and TAC levels before and after treatment in the observation group was higher than that in the control group (P<0.05). The quality of life score in the observation group was significantly higher than that in the control group (P<0.05). Conclusion: The combination of epalrestat and taurine after operation can double the regulation of intraocular osmotic pressure and reduce the stress damage caused by surgery, which is conducive to postoperative visual recovery, reduce postoperative complications and improve the prognosis of patients. |
[1] 张健,李蕾,邓一洁,等.我国糖尿病的流行现状和危险因素分析[J].世界最新医学信息文摘,2018,18(16):94-96.
[2] 赵瑞博,郭永红,张凌子.二甲双胍联合羟苯磺酸钙治疗糖尿病性白内障的疗效及其对IL-1β和MMP-9的影响[J].现代医学,2016,44(7):993-995.
[3] 宋亚玲,张玉芳,焦丽坤,等.复明片联合吡诺克辛滴眼液治疗糖尿病并轻度白内障疗效及对生存质量的影响[J].现代中西医结合杂志,2017,26(36):4053-4055.
[4] 付学玲,江颖,赵晓霞,等.芪明颗粒联合普拉洛芬滴眼液预防糖尿病白内障超声乳化术后黄斑水肿50例[J].中国药业,2015,4(10):82-84.
[5] 金哲.糖尿病性白内障摘除人工晶体植入术的疗效分析及临床研究[J].中国医药指南,2018,16(18):127-128.
[6] 孟凡红,何小松.白内障超声乳化手术的护理配合[J].现代医学,2015,43(3):388-390.
[7] 张姬慧,何晓璐,林泰南.曲安奈德治疗糖尿病患者白内障术后并发症的临床观察[J].海峡药学,2013,25(12):152-153.
[8] 李宪华,庞秀琴,郑蕊.糖尿病患者白内障超声乳化联合人工晶体植入术的临床观察[J].国际眼科杂志,2008,8(6):1170-1172.
[9] SIVAPRASAD S,BUNCE C,CROSBY-NWAOBI R, et al.Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery[J].Cochrane Database Syst Rev,2005,25(1):CD004239.
[10] 张超,王路飞,董宇晨,等.糖尿病性白内障发病机制、流行病学与治疗的新进展[J].中国老年学杂志,2012,32(5):1082-1085.
[11] 熊朝晖,孙朝晖,冯艳霞,等.依帕司他治疗早期糖尿病性白内障的临床评价[J].华南国防医学杂志,2014,28(8):826-827.
[12] NIROGI R, KANDIKERE V, AJJALA D R,et al.LC-MS/MS method for the quantification of aldose reductase inhibitor-Epalrestat and application to pharmacokinetic study[J].J Pharm Biomed Anal,2013,74(2):227-234.
[13] 祖薇,辛志坤.口服药物对增生性糖尿病视网膜病变术后康复效果的影响[J].国际眼科杂志,2014,14(8):1516-1518.
[14] 林伟斌.产前牛磺酸干预生长受限患儿脑发育障碍的效果分析[J].现代医学,2017,45(1):93-96.
[15] 闫文亮.牛磺酸的生物学功能及其在眼用制剂中的应用分析[J].中国药房,2007, 18(30):2390-2391.
[16] 宋旭东,陈翠真,董冰,等.牛磺酸对链脲佐菌素-糖尿病性白内障干预机制初探[J].中华眼科杂志,2003,39(10):605-609.
[17] 袁媛,邱霞.糖尿病性白内障发病机制及治疗研究进展[J].转化医学杂志,2014,3(4):244-245, 256. |